THE PROGNOSTIC AND PREDICTIVE SIGNIFICANCE OF PARTIAL MGMT PROMOTER METHYLATION FOR IDH-WILDTYPE GLIOBLASTOMA PATIENTS

被引：0

作者：

Torre, Matthew ^{[1
]}

Iorgulescu, Bryan ^{[2
]}

机构：

[1] Brigham & Womens Hosp, Boston, MA USA

[2] Dana Farber Canc Inst, Boston, MA USA

来源：

NEURO-ONCOLOGY | 2022年 / 24卷

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

BIOM-29

引用

页码：10 / 10

页数：1

共 50 条

[1] TERT PROMOTER MUTATION AND MGMT PROMOTER METHYLATION-MEDIATED SENSITIVITY TO TEMOZOLOMIDE IN IDH-WILDTYPE GLIOBLASTOMA: IS THERE A LINK?
Gramatzki, Dorothee
Felsberg, Joerg
Hentschel, Bettina
Wolter, Marietta
Schackert, Gabriele
Westphal, Manfred
Regli, Luca
Thon, Niklas
Tatagiba, Marcos
Wick, Wolfgang
Schlegel, Uwe
Krex, Dietmar
Matschke, Jakob
Roth, Patrick
Suresh, Marian
Kamp, Marcel
Rushing, Elisabeth
Pietsch, Torsten
von Deimling, Andreas
Sabel, Michael
Loeffler, Markus
Weller, Michael
Reifenberger, Guido
[J]. NEURO-ONCOLOGY, 2020, 22 : 14 - 14
[2] PROGNOSTIC AND PREDICTIVE SIGNIFICANCE Of MGMT PROMOTER METHYLATION AND PROTEIN EXPRESSION IN GLIOBLASTOMA PATIENTS
Spiegl-Kreinecker, S.
Pirker, C.
Filipits, M.
Loetsch, D.
Buchroithner, J.
Pichler, J.
Silye, R.
Micksche, M.
Fischer, J.
Berger, W.
[J]. NEURO-ONCOLOGY, 2008, 10 (06) : 1080 - 1080
[3] The Association Between the Extent of Glioblastoma Resection and Survival in Light of MGMT Promoter Methylation in 326 Patients With Newly Diagnosed IDH-Wildtype Glioblastoma
Incekara, Fatih
Smits, Marion
van der Voort, Sebastian R.
Dubbink, Hendrik Jan
Atmodimedjo, Peggy N.
Kros, Johan M.
Vincent, Arnaud J. P. E.
van den Bent, Martin
[J]. FRONTIERS IN ONCOLOGY, 2020, 10
[4] Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
Müller Mareike
Staub-Bartelt Franziska
Ehrmann Julia
Hänggi Daniel
Sabel Michael
Felsberg Jörg
Rapp Marion
[J]. Journal of Neuro-Oncology, 2021, 153 : 537 - 545
[5] Does positive MGMT methylation outbalance the limitation of subtotal resection in glioblastoma IDH-wildtype patients?
Mareike, Mueller
Franziska, Staub-Bartelt
Julia, Ehrmann
Daniel, Haenggi
Michael, Sabel
Joerg, Felsberg
Marion, Rapp
[J]. JOURNAL OF NEURO-ONCOLOGY, 2021, 153 (03) : 537 - 545
[6] Molecular differences in IDH wildtype glioblastoma according to MGMT promoter methylation
Kessler, Tobias
Sahm, Felix
Sadik, Ahmed
Stichel, Damian
Hertenstein, Anne
Reifenberger, Guido
Zacher, Angela
Sabel, Michael
Tabatabai, Ghazaleh
Steinbach, Joachim
Sure, Ulrich
Krex, Dietmar
Grosu, Anca-L
Bewerunge-Hudler, Melanie
Jones, David
Pfister, Stefan M.
Weller, Michael
Opitz, Christiane
Bendszus, Martin
von Deimling, Andreas
Platten, Michael
Wick, Wolfgang
[J]. NEURO-ONCOLOGY, 2018, 20 (03) : 367 - 379
[7] The predictive value of partial MGMT promoter methylation for IDH-wild-type glioblastoma patients
Torre, Matthew
Wen, Patrick Y.
Iorgulescu, J. Bryan
[J]. NEURO-ONCOLOGY PRACTICE, 2023, 10 (02) : 126 - 131
[8] Prognostic significance of baseline thyroid variables in IDH-wildtype glioblastoma patients treated with regorafenib
McLean, Aaron Lawson
[J]. JOURNAL OF NEURO-ONCOLOGY, 2023, 164 (1) : 267 - 268
[9] Prognostic significance of baseline thyroid variables in IDH-wildtype glioblastoma patients treated with regorafenib
Aaron Lawson McLean
[J]. Journal of Neuro-Oncology, 2023, 164 : 267 - 268
[10] THE SIGNIFICANCE OF TERT PROMOTER MUTATIONS, TELOMERE LENGTH AND MGMT PROMOTER METHYLATION IN NEWLY DIAGNOSED AND RECURRENT IDH-WILDTYPE GLIOBLASTOMA (GBM): A LARGE MONO-INSTITUTIONAL STUDY
Lombardi, Giuseppe
Giunco, Silvia
Cavallin, Francesco
Angelini, Chiara
Caccese, Mario
Cerretti, Giulia
De Bonis, Pasquale
De Rossi, Anita
Zagonel, Vittorina
[J]. NEURO-ONCOLOGY, 2021, 23 : 15 - 15

← 1 2 3 4 5 →